Article Text

Download PDFPDF
The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer
  1. H. Tsuda*,,
  2. Y. Hashiguchi*,,
  3. S. Nakata*,
  4. M. Deguchi*,
  5. S. Negoro,
  6. O. Ishiko and
  7. K. Yamamoto*
  1. * Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka, Japan
  2. Department of Clinical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
  3. Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka, Japan
  1. Address correspondence and reprint requests to: Hiroshi Tsuda, Department of Obstetrics and Gynecology, Osaka City General Hospital., 2-13-22, Miyakojimahondori Miyakojima Osaka 534–0021, Japan. Email: tsud777{at}ocgh.hospital.city.osaka.jp.

Abstract

In this study, we compare the time to normalization of CA125 after cytoreductive surgery between a paclitaxel-containing regimen and a non-paclitaxel regimen. This study demonstrates that CA125 regression in a paclitaxel-containing regimen was slower than that in a non-paclitaxel regimen. When we determine the CA125 regression rate to predict overall survival in ovarian cancer, we should take into account the kind of chemotherapy regimen, especially the use of paclitaxel.

  • CA125
  • CAP therapy
  • ovarian cancer
  • prognostic factor
  • TP therapy

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.